Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer
Cooperative Group
European Network for Gynaecological Oncological Trial Groups & the Gynecologic Oncology Group
Commercial Sponsor
Merck
Summary
Eligible patients will be randomised to receive standard of care chemo-radiotherapy with cisplatin and external beam radiotherapy and brachytherapy, in addition to pembrolizumab or a pembrolizumab-placebo, to understand the impact on progression-free survival and overall survival.